Early detection and monitoring of mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) patients are key to tackling dementia and providing benefits to patients, caregivers, healthcare providers and society. Digital biomarkers can help identify and monitor subtle cognitive changes in individuals at risk of developing dementia. Furthermore, such tests are able to benefit from advanced analytics for more accurate and personalised results. Artificial intelligence (AI) and machine learning are being increasingly used for applications in Dementia research. We developed the Integrated Cognitive Assessment (ICA) which is a 5-min, self-administered, computerised cognitive assessment tool based on a rapid categorisation task. The ICA is innately independent of language and culture, and can generalise across populations without the need for collection of population-specific normative data. ICA has received CE approval for use in Europe and is cleared by FDA for use in the US. After more than 28 years of symptom therapy in AD, new disease modifying therapies are becoming available which are only effective in early stages of the disease. This further emphasizes the importance of early diagnosis, and highlights the benefits of emerging technologies such as ICA a practical solution to the significant and urgent problem of timely dementia diagnosis.